指南与共识脊柱关节炎

2019年美国风湿病学会/脊柱炎协会/脊柱关节炎研究治疗网络关于强直性脊柱炎和非放射学中轴型脊柱关节炎治疗建议的更新

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
指南 / 共识 · Arthritis Rheumatol · 2019-08-22

该指南更新了2015年关于强直性脊柱炎(AS)和非放射学中轴型脊柱关节炎(SpA)的治疗建议,基于系统文献综述和GRADE方法,新增了关于司库奇尤单抗、依奇珠单抗、托法替布、TNFi生物类似药及生物制剂减停等问题的推荐。主要推荐包括:TNFi作为首个生物制剂优于司库奇尤单抗或依奇珠单抗;对首个TNFi原发无应答者,换用司库奇尤单抗或依奇珠单抗优于换用第二种TNFi;TNFi、司库奇尤单抗和依奇珠单抗优于托法替布;不推荐联用小剂量甲氨蝶呤、严格达标治疗或对稳定期患者减停生物制剂。

要点

  • TNFi推荐作为首个生物制剂,优于司库奇尤单抗或依奇珠单抗。
  • 首个TNFi原发无应答者,换用司库奇尤单抗或依奇珠单抗优于第二种TNFi。
  • 不推荐联用小剂量甲氨蝶呤、严格达标治疗或稳定期减停生物制剂。

核心结论

  • 对于AS和非放射学中轴型SpA,TNFi推荐作为首个生物制剂,优于司库奇尤单抗或依奇珠单抗。
  • 对首个TNFi原发无应答者,推荐换用司库奇尤单抗或依奇珠单抗而非第二种TNFi。
  • TNFi、司库奇尤单抗和依奇珠单抗优于托法替布。
  • 不推荐TNFi联用小剂量甲氨蝶呤,也不推荐严格达标治疗或对稳定期患者减停/减量生物制剂。
  • 柳氮磺吡啶仅推荐用于TNFi禁忌时持续的外周关节炎。

研究设计与样本

  • 基于2015年指南的20个药物治疗临床问题更新系统文献综述,并新增26个关于药物治疗、达标治疗策略和影像学使用的问题。
  • 采用GRADE方法评估证据质量并形成推荐,要求投票小组至少70%同意。

主要发现

  • AS和非放射学中轴型SpA的推荐相似。
  • 新问题涉及司库奇尤单抗、依奇珠单抗、托法替布、TNFi生物类似药及生物制剂减停等。
  • 对疾病活动度不明确者,脊柱或骨盆磁共振成像可辅助评估。
  • 不推荐常规连续脊柱X线监测放射学变化。

关键数值与推荐

  • TNFi推荐作为首个生物制剂,优于司库奇尤单抗或依奇珠单抗。
  • 首个TNFi原发无应答者,司库奇尤单抗或依奇珠单抗优于第二种TNFi。
  • TNFi、司库奇尤单抗和依奇珠单抗优于托法替布。
  • 不推荐TNFi联用小剂量甲氨蝶呤。
  • 不推荐严格达标治疗或对稳定期患者减停/减量生物制剂。

临床怎么用

  • 选择首个生物制剂时优先选用TNFi。
  • 首个TNFi原发无应答时,优先换用司库奇尤单抗或依奇珠单抗而非第二种TNFi。
  • 避免TNFi联用小剂量甲氨蝶呤、严格达标治疗及对稳定期患者减停生物制剂。
  • 疾病活动度不明确时可考虑脊柱或骨盆磁共振成像辅助评估。
  • 不常规连续脊柱X线监测放射学变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). METHODS: We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat-to-target strategy, and use of imaging. New questions addressed the use of secukinumab, ixekizumab, tofacitinib, tumor necrosis factor inhibitor (TNFi) biosimilars, and biologic tapering/discontinuation, among others. We used the Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations and required at least 70% agreement among the voting panel. RESULTS: Recommendations for AS and nonradiographic axial SpA are similar. TNFi are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. TNFi, secukinumab, and ixekizumab are favored over tofacitinib. Co-administration of low-dose methotrexate with TNFi is not recommended, nor is a strict treat-to-target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNFi are contraindicated. For patients with unclear disease activity, spine or pelvis magnetic resonance imaging could aid assessment. Routine monitoring of radiographic changes with serial spine radiographs is not recommended. CONCLUSION: These recommendations provide updated guidance regarding use of new medications and imaging of the axial skeleton in the management of AS and nonradiographic axial SpA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019. PMID: 31436036. doi:10.1002/art.41042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。